Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The combination treatment reduced the need for ...

FOSTER CITY, Calif. -- The world's largest randomized trial of COVID-19 treatments found "conclusive evidence" that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has ...

Please provide your email address to receive an email when new articles are posted on . Remdesivir did not reduce adverse cardiovascular or kidney events in the study cohort. Remdesivir use was ...

A 25% lower all-cause mortality is associated with timely initiation of remdesivir in immunocompromised patients hospitalized for COVID-19. Among patients with immunocompromising conditions who were ...

There’s no evidence showing that remdesivir, the first treatment approved for COVID-19, killed patients taking the drug. The antiviral drug is still approved by the U.S. Food and Drug Administration ...

An early look at results from one trial of a drug being tested to treat COVID-19 indicates patients experienced rapid recovery from fever and respiratory symptoms, with nearly all patients discharged ...